(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of 251.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Xenon Pharmaceuticals's revenue in 2026 is $7,500,000.On average, 17 Wall Street analysts forecast XENE's revenue for 2026 to be $394,102,526, with the lowest XENE revenue forecast at $0, and the highest XENE revenue forecast at $2,028,468,881. On average, 16 Wall Street analysts forecast XENE's revenue for 2027 to be $6,880,798,270, with the lowest XENE revenue forecast at $1,060,599,444, and the highest XENE revenue forecast at $20,361,191,067.
In 2028, XENE is forecast to generate $27,941,096,308 in revenue, with the lowest revenue forecast at $6,851,665,593 and the highest revenue forecast at $86,857,105,620.